These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 34108743)

  • 1. Nested g-computation: A causal approach to analysis of censored medical costs in the presence of time-varying treatment.
    Spieker AJ; Ko EM; Roy JA; Mitra N
    J R Stat Soc Ser C Appl Stat; 2020 Nov; 69(5):1189-1208. PubMed ID: 34108743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzing medical costs with time-dependent treatment: The nested g-formula.
    Spieker A; Roy J; Mitra N
    Health Econ; 2018 Jul; 27(7):1063-1073. PubMed ID: 29663579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A regression framework for a probabilistic measure of cost-effectiveness.
    Illenberger N; Mitra N; Spieker AJ
    Health Econ; 2022 Jul; 31(7):1438-1451. PubMed ID: 35460149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiparametric Estimation of Longitudinal Medical Cost Trajectory.
    Li L; Wu CH; Ning J; Huang X; Tina Shih YC; Shen Y
    J Am Stat Assoc; 2018; 113(522):582-592. PubMed ID: 30853736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented and doubly robust G-estimation of causal effects under a Structural nested failure time model.
    Mertens K; Vansteelandt S
    Biometrics; 2018 Jun; 74(2):472-480. PubMed ID: 28742252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Nested Cumulative Failure Time Models to Estimate the Effects of Interventions.
    Picciotto S; Hernán MA; Page JH; Young JG; Robins JM
    J Am Stat Assoc; 2012; 107(499):. PubMed ID: 24347749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-part model for censored medical cost data.
    Tian L; Huang J
    Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
    Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
    Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
    Latimer NR; White IR; Tilling K; Siebert U
    Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity score and doubly robust methods for estimating the effect of treatment on censored cost.
    Li J; Handorf E; Bekelman J; Mitra N
    Stat Med; 2016 May; 35(12):1985-99. PubMed ID: 26678242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating mean total costs in the presence of censoring: a comparative assessment of methods.
    Young TA
    Pharmacoeconomics; 2005; 23(12):1229-42. PubMed ID: 16336017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical modeling of longitudinal medical cost trajectory: renal cell cancer care cost analyses.
    Wang S; Shen Y; Shih YT; Xu Y; Li L
    Biostatistics; 2020 Jul; ():. PubMed ID: 34269395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic supracervical hysterectomy compared with second-generation endometrial ablation for heavy menstrual bleeding: the HEALTH RCT.
    Cooper K; Breeman S; Scott NW; Scotland G; Hernández R; Clark TJ; Hawe J; Hawthorn R; Phillips K; Wileman S; McCormack K; Norrie J; Bhattacharya S
    Health Technol Assess; 2019 Sep; 23(53):1-108. PubMed ID: 31577219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of cervical cancer treatment: population-based estimates from Ontario.
    Pendrith C; Thind A; Zaric GS; Sarma S
    Curr Oncol; 2016 Apr; 23(2):e109-15. PubMed ID: 27122978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.
    Young JG; Vatsa R; Murray EJ; Hernán MA
    Trials; 2019 Sep; 20(1):552. PubMed ID: 31488202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression analysis of incomplete medical cost data.
    Lin DY
    Stat Med; 2003 Apr; 22(7):1181-200. PubMed ID: 12652561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SENSITIVITY ANALYSIS FOR UNMEASURED CONFOUNDING IN COARSE STRUCTURAL NESTED MEAN MODELS.
    Yang S; Lok JJ
    Stat Sin; 2018 Oct; 28(4):1703-1723. PubMed ID: 30853756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Determinants of Multiple Treatment Episodes for Substance Abusers.
    Goodman AC; Hankin JR; Kalist DE; Peng Y; Spurr SJ
    J Ment Health Policy Econ; 2001 Jun; 4(2):65-77. PubMed ID: 11967467
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.